INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. It refers to a broad spectrum of liver diseases which vary from nonalcoholic steatohepatitis (NASH) to progressive fibrosis and cirrhosis with portal hypertension [1, 2] . The clinical definition of NAFLD depends on the presence of hepatic fat accumulation more than 5% of the liver weight and the exclusion of other causes of lipid infiltration in the liver (absence of significant alcohol intake, hepatic viral infections, or other specific causes of liver disease) [1] .
Different theories have tried to identify the pathogenesis of progressive inflammation and fibrosis in NAFLD. Previously, Day and colleagues proposed the "two-hit theory", in which there is an impairment in fatty acid metabolism in hepatocytes, leading to a net accumulation of triglycerides within the liver, combined with peroxidation of lipid accumulated within hepatocytes [3] . Recently, Tilg and colleagues [4] suggested the "Multiple Parallel Hits Hypothesis" as a pathogenesis of NASH. Factors as excessive lipolysis, lipopolysaccharide accumulation in the liver, stimulation of Toll-like receptors, and endocrinal function of adipose tissue, are thought to be linked with the degree of steatosis and fibrosis [4] .
J Gastrointestin Liver Dis, March 2017 Vol. 26 No 1: 59-67 NAFLD is asymptomatic in most patients. If present, symptoms include right upper quadrant abdominal pain, fatigue, malaise, hepatomegaly and -to a lesser extent -splenomegaly. A mild elevation in the level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels is often associated with these symptoms [5] . Although lifestyle modifications, calorie restriction, and weight loss are the general measures for management of NAFLD, compliance to this restricted lifestyle is difficult to be achieved [6] .
Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene) is a naturally occurring polyphenol, which activates AMP-activated protein kinase (AMPK) and silent information regulation 2 homologue 1 (SIRT1). Resveratrol has been recently linked to many beneficial actions such as anti-inflammatory, antioxidant, and calorie restriction-like effects [7] [8] [9] . All these properties make resveratrol a promising option for management of NAFLD through its inhibitory effects on lipid accumulation.
However, recent clinical trials show controversy over the efficacy of resveratrol for the management of NAFLD [13, 14] . Therefore, we performed a systematic review and metaanalysis study to assess the effectiveness of resveratrol for the management of NAFLD by searching different bibliographic databases for published randomized controlled trials (RCTs).
METHODS
We followed PRISMA statement guidelines during the preparation of this review and meta-analysis [12] .
Inclusion and exclusion criteria
We included RCTs using the following criteria: 1) studies which examined the efficacy of resveratrol in NAFLD; 2) studies in which population consisted of patients with a clinical and histological diagnosis of NAFLD; and 3) studies written in English language. In the case of multiple reports for the same study population, we analyzed data of the most complete dataset. Studies were excluded for the following reasons: 1) studies do not provide sufficient data reliable for pooling in the meta-analysis, and 2) thesis and conference papers.
Literature search strategy
We searched all published RCTs in the following electronic databases: PubMed, Scopus, Web of Science and Cochrane Central. We used Mesh database and the following search queries: (("resveratrol" ). Three authors screened the title and abstract of retrieved records for eligibility. Full-texts of potentially eligible studies were reviewed, for selecting the eligible studies for meta-analysis.
Data extraction
Three authors extracted the data independently using an online data extraction form. The extracted data included the following: 1) study design; 2) study population; 3) risk of bias domains, and 4) study outcomes: the degree of liver fibrosis, markers of liver damage, lipid profile, anthropometric index, serum cytokines, and glucose metabolism parameters.
Quality assessment
The quality of the retrieved RCTs was assessed according to Cochrane Handbook of systematic reviews of interventions 5.1.0 (updated March 2011). Risk of bias assessment included the following domains: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias; the authors' judgment is categorized as 'Low risk' , 'High risk' or 'Unclear risk' of bias. We used the quality assessment table provided in the same book (part 2, Chapter 8.5) [13] .
Measures of treatment effect
The primary outcome measurements in studies assessing the efficacy of resveratrol in NAFLD were: 1) treatment effect on liver histology and degree of fibrosis assessed by transient elastography score [14] ;
2) markers of liver damage: serum ALT, serum AST and total bilirubin levels;
3) lipid profile: total cholesterol, HDL, LDL and triglyceride levels; 4) anthropometric index: body mass index (BMI), waist circumference (WC), head circumference (HC), waist-hip ratio (WHR) and weight (kg); 5) glucose metabolic parameters: blood glucose level, insulin level and HOMA2-IR; 6) serum cytokines: tumor necrosis factor (TNF-a), cytokeratin-18 (CK-18), interleukin-6 (IL-6) and C-reactive protein (CRP) levels.
Dealing with missing data
In the case of a missing standard deviation (SD) of mean change from baseline, this was calculated from the standard error or 95% confidence interval (CI) according to Altman [15] .
Data synthesis
Continuous data was pooled as mean difference (MD) in a meta-analysis model. Dichotomous data was pooled as relative risk (RR) in a random-effect model. We used Review Manager 5.3 for windows.
Assessment of heterogeneity
Heterogeneity was assessed by the visual inspection of the Forest plots and measured by I-square and Chi-square tests. Chisquare test was used to test the existence of significant heterogeneity while I-square quantified this heterogeneity if present. I-Square test was interpreted according to recommendations of Cochrane Handbook of systematic reviews and meta-analysis (0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; and 75% to 100%: considerable heterogeneity). Chi-square P<0.1 was set as a level of significant heterogeneity.
Sensitivity analysis
In order to resolve detected statistical heterogeneity, we performed sensitivity analysis excluding one study in each scenario.
Publication bias
According to Egger and colleagues [16, 17] , publication bias assessment is not reliable for less than 10 pooled studies. Therefore, in the present study, we could not assess the existence of publication bias by Egger's test for funnel plot asymmetry.
RESULTS

Search results
We retrieved 230 unique citations. After the initial title and abstract screening, 19 full texts were retrieved and screened for eligibility: 15 articles were excluded and four RCTs (five reports, n=158 patients) were included in this study (See PRISMA flow diagram, Fig. 1 ). (Reasons for study exclusion are shown in Supplementary File 1).
Characteristics of included studies
Among the four included RCTs, two trials included only overweight or obese patients diagnosed with NAFLD [10, 18] . In two trials resveratrol was administrated at a dose of 300mg and 500mg for three months [11, 19] , in one study at a dose of 1500mg daily for six months [18] , and in one study a dose of 3000mg daily was utilized and followed up the patients were followed-up only for two months [10] . One trial recommended a healthy diet and regular exercise for its participants [19] , while the remaining trials asked their patients to maintain usual lifestyle and habitual dietary intake. Summary of included studies and their main results are shown in Table I and baseline characteristics of their populations are shown in Table II .
Quality of the included studies
The quality of the included studies is from moderate to high quality according to the Cochrane risk of bias assessment tool. The summary of quality assessment domains of included studies is shown in Fig.2 (authors' judgments with justifications are shown in Supplementary File 2).
Liver histology and degree of fibrosis
Only one study assessed the effect of resveratrol on liver histology and degree of fibrosis [19] . The mean change in the degree of fibrosis was -0.84 in the resveratrol group vs. 0.06 in the placebo group. This detected difference was not statistically significant (p=0.09). However, the number of patients with steatosis grade 2/3 was significantly lower in the resveratrol group compared to the placebo group at the end of follow-up (p=0.02).
Markers of liver damage
Resveratrol group did not show a statistically significant reduction in serum ALT compared to the placebo group (MD -2.89, 95%CI [-15.66, 9 .88], p=0.66); pooled studies showed significant heterogeneity which was best resolved by excluding the Chachay et al. trial [10] , the only trial that reported significant increase in serum ALT in the resveratrol group. Serum AST did not decrease significantly in the resveratrol group in comparison to the placebo group (MD -3.59, 95%CI [-13.82, 6 .63], p=0.49); pooled studies were also heterogeneous, which was best resolved by excluding Chachay et al. [10] . The MD in the total bilirubin level did not favor either of the two groups (MD -0.09, 95%CI [-0.44, 0.26], p=0.61); pooled studies were homogeneous (p>0.1) (Fig. 3) . (Fig. 4) . . Pooled studies showed significant heterogeneity which was best resolved by excluding Chachay et al. [10] (Fig. 5) .
Anthropometric index
Glucose metabolism parameters
Serum cytokines
In terms of inflammatory markers, the overall effect estimate did not favor the resveratrol group in terms of: TNF-α (MD -0. (Fig. 6) . (Fig. 7) .
Lipid profile
Sensitivity analysis
Statistically significant heterogeneity was detected in most of the pooled outcomes, and it was best resolved by excluding Chachay et al. [10] in the following outcomes: serum ALT, serum AST, glucose level, HOMA-IR level, CK-18 level, and triglyceride level. Moreover, after removing Chachay et al. study, the overall effect estimate favored the resveratrol group in the following outcomes: serum ALT, glucose level, HOMA-IR level, and CK-18 level. Chachay et al. was a double-blinded RCT using resveratrol at a dose of 3000 mg for 8 weeks only and required its patients to maintain their usual lifestyle and habitual dietary intake (Supplementary File 3) . 
DISCUSSION
Summary of the main results
Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene) is a naturally occurring polyphenol, which activates AMPK and SIRT1; thereby, it mimics a condition of caloric restriction as shown in a number of in vitro and in vivo studies [20, 21] . The presented meta-analysis shows that there is no sufficient evidence to support the efficacy of resveratrol in the management of NAFLD, as resveratrol did not show a significant reduction in the degree of fibrosis, or in the level of markers of liver damage and inflammatory markers.
In addition, current published evidence shows a significant heterogeneity. Two included RCTs showed a beneficial effect of resveratrol in comparison with the lifestyle modification alone [11, 19] . In contrast, the other two RCTs reported that resveratrol has no consistent therapeutic benefit in the management of NAFLD [10, 18] . We could not perform a further subgroup analysis based on patients' characteristics due to the unavailability of relevant data.
Serum ALT, AST and total bilirubin levels become elevated with liver damage and biliary obstruction, and are therefore used as indicators of the progression of NAFLD [22, 23] . AboZaid et al. [24] reported a significant reduction in the levels of ALT, AST and GGT in induced-NAFLD rats medicated with resveratrol for 6 weeks. Moreover, in terms of the anti-oxidative effect of resveratrol, Schmatz et al. [25] demonstrated that resveratrol significantly prevented the rise of AST, ALT and GGT activities in diabetic rats' groups. In contrast to animal studies, published human trials showed no consistent therapeutic benefits in terms of serum ALT and AST. Our pooled results showed that resveratrol neither attenuates the level of liver damage nor protects against fibrosis.
Obesity is considered as a major risk factor for severe hepatic fibrosis. Chang et al. [26] found that BMI categories are positively correlated with an increased incidence of NAFLD, suggesting that obese patients might have an increased risk of developing NAFLD. Previous studies in rodent models have shown that resveratrol can inhibit NAFLD by decreasing body weight, as well as other obesity-related complications such as blood glucose and LDL-cholesterol [23, 27] . According to the mentioned studies, anthropometric indexes have a crucial role in assessing resveratrol efficacy. None of the included RCTs in this review showed significant differences between the resveratrol and placebo groups in terms of anthropometric index, which runs in accordance with our pooled results. Regarding glucose metabolism, the previous animal study showed a significant decrease in blood glucose level in mice treated with resveratrol [20, 28] . Our pooled analysis showed no beneficial effect of resveratrol on glucose metabolism parameters, which is consistent with all published relevant RCTs except Chen et al. study, which reported a significant decrease in the blood glucose level.
Cytokines as TNF-α, IL6 and serum CK-18 play a key role in the pathogenesis of many metabolic diseases through either its inhibitory or a pro-inflammatory action [29, 30] . Seo et al. conducted a 4-year longitudinal study and found significantly higher levels of TNF-α in subjects who developed NAFLD compared to those who did not [31] . In addition, IL-6 expression level was found to be positively correlated with the degree of inflammation, fibrosis, and systemic inflammatory response in patients with NAFLD [30] . Because of resveratrol anti-inflammatory properties, it is assumed that resveratrol supplementation might be effective in managing NAFLD and restraining its progression. Previous animal studies showed that resveratrol protects the liver against steatosis and fibrosis via activation of Sirt1, leading to the inactivation of NF-κB and inhibition of TNF-α [32, 33] . In contrast, available evidence was not sufficient to show a beneficial effect of resveratrol in decreasing the cytokines level among NAFLD patients, the trial by Chen et al. [11] was the only published clinical trial which demonstrated a significant reduction in TNF-α and IL-6 in the resveratrol group. Our pooled results did not favor the resveratrol group for any inflammatory markers.
Overall completeness
Of the total of 158 patients in the four RCTs, there were 7 discontinuations (resveratrol group = 5 and placebo group = 2). Reasons included adverse events, and consent withdrawn. However, we believe that this is not likely to affect the study outcomes because of the very low rate of discontinuations.
Quality of the evidence
We performed all steps in strict accordance to the Cochrane Handbook of systematic reviews for interventions and followed the PRISMA checklist. This evidence is based on RCTs, search methods and eligibility criteria were well defined.
Limitations
We acknowledge that our analysis has certain limitations, related to the design of the included studies. The primary outcomes used in this review were only biochemical and "proxy markers" of liver damage or metabolic control in NAFLD. Although the use of liver enzymes as markers in NAFLD is controversial, there are no other commonly established noninvasive biomarkers for use in clinical NAFLD/NASH trials. Only one included RCT assessed the effect of resveratrol on liver histology and degree of fibrosis by the transient elastography score. All included RCTs administered resveratrol at different doses, followed up patients for variable periods of time, and recommended different dietary habits. Those methodological heterogeneities led to significant statistical heterogeneity, sensitivity and subgroup analysis failed to resolve the heterogeneity. Variables as sex, race, and severity of fatty infiltration were not investigated in the previous literature, so it is hard to generalize the results of our analysis beyond the characteristics of the included population.
CONCLUSIONS
Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol neither attenuates liver fibrosis nor shows a significant decrease in any of the parameters of NAFLD. Further larger and longer duration trials are required to study the correlation between lifestyle and dietary modifications and the efficacy of resveratrol.
